TKI联合替吉奥化疗序贯治疗非小细胞肺癌患者EGFR-TKI获得性耐药的疗效观察

doi:10.3969/j.issn.1006-6233.2018.10.034

Abstract
Figure/Table
References
Related Citation (11)

Download: PDF (1342 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore clinical effect of tyrosine kinase inhibitor (TKI) combined with S-1 chemotherapy in treatment of EGFR-TKI acquired resistance to patients with non-small cell lung cancer. Methods: 64 cases of patients with mutations in NSCLC and EGFR genes treated in our hospital were selected as the study objects, and were divided into control group and the study group according to different treatment methods, 32 cases in each group. Control group were given S-1 combined with cisplatin chemotherapy. the study group were combined with TKI treatment on the basis of control group. Tumor remission rate and serum tumor markers, carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA211), and carbohydrate antigen (CA199) levels before and after treatment were contrasted in the two groups. Types of adverse reactions were reported, and patients without progression of survival (PFS) within 1 years were analyzed by using Kaplan-Meier survival analysis. Results: The tumor remission rate in the study group was higher than that in the control group, and the difference was statistically significant.(75.00%VS46.88% P＜0.05). After treatment, serum CEA, CYFRA211 and CA199 levels decreased in the two groups, and the decreasing in the study group was higher than that in control group (P<0.05). Diarrhea, nausea, vomiting, myalgia, hair loss, fever, fatigue, anemia, thrombocytopenia, granulocyte reduction, and transaminase abnormalities occurred in the two groups after treatment. There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05).The PFS of the study group was higher than that of the control group, and the difference between the two groups was statistically significant.(6.83±1.62VS 8.71±1.85 P＜0.05). Conclusion: Patients with mutations in NSCLC and EGFR genes treated by TKI combined with S-1 chemotherapy after EGFR-TKI acquired resistance, it can delay the progression of the disease and prolong patients' survival time, with mild adverse reactions. It is a highly effective treatment.

Key words： Non small cell lung cancer Epidermal growth factor receptor tyrosine kinase inhibitor Acquired resistance S-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jingjie
	MA Jianxin
	WANG Mu
	et al

Cite this article:

ZHANG Jingjie,MA Jianxin,WANG Mu, et al. Observation on Curative Effect of TKI Combined with S-1 Chemotherapy in Treatment of EGFR-TKI Acquired Resistance to Patients with Non-small Cell Lung Cancer[J]. HeBei Med, 2018, 24(10): 1722-1726.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.10.034 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I10/1722

[1] 田家伟,韩淑华.核苷酸还原酶M1在晚期非小细胞肺癌治疗和预后中的作用[J].中国肺癌杂志,2015(6):381~386.
[2] 王皓.非小细胞肺癌靶向治疗药物的研究进展[J].中国药科大学学报,2014,34(2):692~695.
[3] Jackman D,Pao W, Riely G J,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.[J].Clin Oncol ,2010, 28(2):357~360.
[4] Lencioni R, Llovet J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Seminars in Liver Disease,2010:52~60.
[5] Trotti A,Colevas AD,Setser A,et al.Development of acomprehensive grading system for the adverse effects of cancer treatment[J].Semin Badiat Oncol,2003,13(3):176~181.
[6] 张伟,何建军,许静,等.721例非小细胞肺癌临床病理学特征分析[J].现代肿瘤医学,2016,24(15):2393~2397.
[7] 邢舴,呼群,苏乌云,等.非小细胞肺癌免疫组化指标的表达与EGFR基因突变的相关性[J].医学研究生学报,2017,30(3):275~278.
[8] 王颖轶,陈书长.STATS、VEGF和EGFR在非小细胞肺癌中表达的相关研究[J].现代肿瘤医学,2014(4):826~829.
[9] Wang X, Goldstein D, Crowe P J, et al. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence[J]. Oncotargets & Therapy, 2016, 9:5461.
[10] 李向莲,唐雪莉,李幼平,等.EGFR-TKI与化疗比较一线治疗晚期非小细胞肺癌有效性和安全性的系统评价[J].中国循证医学杂志,2016,16(2):191~199.
[11] Mou K, Yang F L, Jiu-De Q I, et al. Effect of chemotherapy alternately targeted drugs on the long term prognosis in EGFR mutation positive patients with advanced NSCLC[J]. Modern Medical Journal, 2016,44(4):516~519.
[12] Janne P A, Wang X F, Socinski M A. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406[J]. Asco Meeting Abstracts, 2010,28(15):7503~7510.
[13] 李剑英,吴晓敏,何灵慧,等.EGFR-TKI联合化疗治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效分析[J].中国癌症杂志,2013(6):462~466.
[14] 李佳旻,洪群英,张新,等.化疗序贯EGFR-TKI治疗晚期非小细胞肺癌EGFR-TKI获得性耐药患者的效果及安全性[J].中华医学杂志,2014,94(30):2342~2345.
[15] Goldberg SB,Oxnard GR,Digumarthy S,et al.Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine ki-naseinhibitors[J].Oncologist,2013,18(11):1214~1220.